Novel resistance-nodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3

Antimicrobial Agents and Chemotherapy
Sze Lok ChauElizabeth T S Houang

Abstract

Resistance-nodulation-cell division type efflux pump AdeDE was identified in acinetobacters belonging to genomic DNA group 3. Inactivation of adeE showed that it may be responsible for reduced susceptibility to amikacin, ceftazidime, chloramphenicol, ciprofloxacin, erythromycin, ethidium bromide, meropenem, rifampin, and tetracycline. However, unlike what was found for other similar efflux systems, the open reading frame for the outer membrane component was not found downstream of the adeDE gene cluster.

References

Apr 1, 1996·Clinical Microbiology Reviews·E Bergogne-Bérézin, K J Towner
Jan 30, 1999·Antimicrobial Agents and Chemotherapy·T MineT Tsuchiya
Dec 6, 2000·Microbiology and Molecular Biology Reviews : MMBR·M PutmanW N Konings

❮ Previous
Next ❯

Citations

Jun 9, 2005·Advanced Drug Delivery Reviews·Ayush Kumar, Herbert P Schweizer
Aug 9, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Louis B Rice
May 5, 2010·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Alexey RuzinPatricia A Bradford
Oct 29, 2009·The Journal of Antimicrobial Chemotherapy·Sasitorn ChusriJulian Davies
Aug 31, 2010·Current Opinion in Infectious Diseases·Jennifer HoDavid L Paterson
Nov 26, 2008·Antimicrobial Agents and Chemotherapy·Alejandro BeceiroUNKNOWN Spanish Group for Nosocomial Infection (GEIH)
Dec 19, 2007·Antimicrobial Agents and Chemotherapy·Laurence Damier-PiollePatrice Courvalin
Jan 5, 2011·Antimicrobial Agents and Chemotherapy·Ignasi RocaJordi Vila
Dec 22, 2010·Antimicrobial Agents and Chemotherapy·Sébastien CoyneBruno Périchon
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Mar 25, 2011·Journal of Molecular Microbiology and Biotechnology·Karl A HassanIan T Paulsen
Jul 23, 2011·Journal of Molecular Microbiology and Biotechnology·Bart A EijkelkampMelissa H Brown
Aug 15, 2009·Drugs·Xian-Zhi Li, Hiroshi Nikaido
Dec 17, 2008·Future Microbiology·Matteo BassettiLaura Nicolini
Dec 6, 2008·Folia Histochemica Et Cytobiologica·Piotr WieczorekElzbieta Tryniszewska
Apr 26, 2007·Annals of Medicine·Keith Poole
Aug 30, 2005·Current Opinion in Microbiology·Jodi M Thomson, Robert A Bonomo
Jun 29, 2011·FEMS Microbiology Reviews·Hiroshi Nikaido, Jean-Marie Pagès
Mar 8, 2011·International Journal of Antimicrobial Agents·Jenny Cortez-Cordova, Ayush Kumar
Jun 23, 2016·Canadian Journal of Microbiology·Sirawit PagdepanichkitRungtip Chuanchuen
Jan 26, 2017·The Journal of Microbiology·Ming-Feng LinChung-Yu Lan
Jun 27, 2018·Antimicrobial Agents and Chemotherapy·María Pérez-VarelaJordi Barbé
May 26, 2005·The Journal of Antimicrobial Chemotherapy·Keith Poole
Mar 15, 2006·Journal of Medical Microbiology·Yiu Wai ChuElizabeth T S Houang
Oct 28, 2017·The Journal of Microbiology·Bora Shin, Woojun Park
Nov 18, 2019·Current Infectious Disease Reports·David A ButlerEric Wenzler
Dec 18, 2014·World Journal of Clinical Cases·Ming-Feng Lin, Chung-Yu Lan
Apr 28, 2021·Antimicrobial Agents and Chemotherapy·Vanessa Kornelsen, Ayush Kumar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.